Blog

The Impact of Diet and Exercise in Psoriasis

Author and Disclosure Information

 

It is well established that increased body mass index and weight gain are risk factors for psoriasis, and the prevalence of obesity in patients with psoriasis is higher than in the general population. However, there are limited data concerning the role of diet and exercise in psoriasis.

Naldi et al (Br J Dermatol. 2014;170:634-642) assessed the impact of dietary intervention in combination with physical exercise for weight loss on improving psoriasis in overweight or obese individuals. The investigators evaluated 303 overweight or obese patients with moderate to severe chronic plaque psoriasis who did not achieve clearance after 4 weeks of continuous systemic treatment. Patients were randomized to 2 regimens: a 20-week quantitative and qualitative dietary plan associated with physical exercise for weight loss, or simple informative counseling at baseline about the utility of weight loss for clinical control of psoriatic disease. The main outcome was any reduction of the psoriasis area and severity index (PASI) from baseline to week 20.

Analysis of the intention-to-treat population showed a median reduction in the PASI score of 48% (95% confidence interval, 33.3%-58.3%) in the diet arm and 25.5% (95% confidence interval, 18.2%-33.3%) in the counseling arm (P=.02). The weight-loss target (a ≥5% reduction from baseline) was reached by 29.8% of patients in the diet arm compared to 14.5% in the counseling arm (P=.001).

The authors concluded that a 20-week dietetic intervention associated with increased physical exercise reduced psoriasis severity in systemically treated overweight or obese patients with active psoriasis.

What’s the issue?

As we would expect, a direct dietary intervention had a great impact on the study population. Will you try to adopt a structured dietary intervention in your patient population?

We want to know your views! Tell us what you think.

Recommended Reading

Pityriasis Rubra Pilaris Triggered by Photodynamic Therapy With Response to Tumor Necrosis Factor α–Blocking Agents and Acitretin
MDedge Dermatology
Polyarteritis nodosa gene discovery raises new possibilities for field
MDedge Dermatology
In the Pipeline for Psoriasis: Upcoming Psoriasis Treatments
MDedge Dermatology
Benzophenones named 2014 Contact Allergen of the Year
MDedge Dermatology
FDA approves PDE-4 inhibitor for treating psoriatic arthritis
MDedge Dermatology
Tofacitinib found noninferior to etanercept for treating psoriasis
MDedge Dermatology
Psoriatic pruritus improves with TrkA-blocking drug
MDedge Dermatology
Ustekinumab again linked to cardiovascular events
MDedge Dermatology
Key studies show distinctive features of pediatric psoriasis
MDedge Dermatology
Denver AAD 2014
MDedge Dermatology

Related Articles